birth. On the other hand, DGAT1 deficient mice are viable (Yen *et al*., *J. Lipid Research*, 2008, 49, 2283).


Despite this perinatal lethal phenotype, the metabolic role of DGAT2 has been mostly understood from effort exploiting anti-sense oligonucleotides (ASO) in rodents. In this setting, DGAT2 knockdown in *ob/ob* mice with a DGAT2 gene-specific ASO resulted in a dose dependent decrease in very low density lipoprotein ("VLDL") and a reduction in plasma TG, total cholesterol, and ApoB (Liu, *et al*., *Biochim. Biophys Acta* 2008, 1781, 97). In the same study, DGAT2 antisense oligonucleotide treatment of *ob/ob* mice showed a decrease in weight gain, adipose weight and hepatic TG content. *Id.* In another study, antisense treatment of ob/ob mice improved hepatic steatosis and hyperlipidemia (Yu, *et al*., *Hepatology*, 2005, 42, 362). Another study showed that diet-induced hepatic steatosis and insulin resistance was improved by knocking down DGAT2 in rats. These effects seem to be unique to inhibition of DGAT2, as ASO against DGAT1 did not lead to similar beneficial effects. Although the molecular mechanism behind these observations remains uncertain, the collective data suggest that suppression of DGAT2 is associated with reduced expression of lipogenic genes (SREBP1c, ACC1, SCD1, and mtGPAT) and increased expression of oxidative/thermogenic genes (CPT1, UCP2) (Choi *et al*., *J. Bio. Chem*., 2007, 282, 22678).

In light of the above, inhibitors of DGAT2 are useful for treating disease related to the spectrum of metabolic syndrome such as hepatic steatosis, non-alcoholic steatohepatitis (NASH), fibrosis, type-2 diabetes mellitus, obesity, hyperlipidemia, hypercholesterolemia, atherosclerosis, cognitive decline, dementia, cardiorenal diseases such as chronic kidney diseases and heart failure and related diseases and conditions.

DGAT2 inhibitor compounds are described in WO2021064590, WO2016036633, WO2016036636, WO2016036638, WO2018093696, WO2018093698, WO2013150416, US20150259323, WO2015077299, WO2017011276, WO2018033832, US201801628, WO2003053363.

SUMMARY ~~OF THE INVENTION~~


The present ~~invention~~disclosure relates to compounds represented by Formula **I**:



I

as well as pharmaceutically acceptable salts, esters, and prodrugs thereof, which are DGAT2 inhibitors.

In one aspect, there is provided a compound of Formula I:



I , or a pharmaceutically acceptable salt thereof wherein:

X, Y, and Z are independently selected from N or C(R^5);

R^1 is

(1) phenyl unsubstituted or substituted with 1, 2, or 3 R^6,

(2) 5- or 6-membered heteroaryl containing 1, 2, 3 or 4 heteroatoms independently selected from N, O, and S, wherein the heteroaryl is unsubstituted or substituted with 1, 2, or 3 R^6, or

(3) 8- to 10- membered fused heteroaryl containing 1, 2, or 3 heteroatoms independently selected from N, O, and S, wherein the heteroaryl is unsubstituted or substituted with 1, 2, or 3 R^6;

R^{2a} and R^{2b} are independently selected from

(1) hydrogen,

(2) halogen,

(3) hydroxy,

(4) (C_{1-6})alkyl,

(5) (C_{1-6})haloalkyl,

(6) R^{2a} and R^{2b} join to form spiro(C_{3-8})cycloalkyl unsubstituted or optionally mono-substituted, disubstituted with C_{1-3}alkyl, halogen, or OH, or

(7) R^{2a} and R^{2b} join to form spiro 4- to 8- membered heterocyclyl containing 1 or 2 heteroatoms independently selected from N, O, and S wherein the heterocyclyl is unsubstituted or substituted by 1, 2, or 3 R^7;

R^3 is

(1) 4- to 7-membered heterocyclyl containing 1, 2, or 3 heteroatoms independently selected from N, O and S,

(2) 5- or 6-membered heteroaryl containing 1, 2, or 3 heteroatoms independently selected from N, O, and S,

(3) -(C_{1-6})alkyl-heteroaryl, wherein the heteroaryl is a 5- or 6-membered heteroaryl containing 1, 2, or 3 heteroatoms independently selected from N, O and S,

(4) -(C_{1-6})alkyl-aryl,

(5) -(C_{1-6})alkyl-heterocyclyl, wherein the heterocyclyl is a 3- to 6-membered ring containing 1 or 2 heteroatoms independently selected from N, O and S,

(6) -(C_{1-6})alkyl,

(7) -(C_{3-6})cycloalkyl,

(8) -(C_{1-6})hydroxyalkyl,

(9) -(C_{1-6})alkyl-$S(O)_2$-$NR^{8a}R^{8b}$, or

(10) -(C_{1-6})alkyl-$S(O)_2$-(C_{1-3})alkyl,

wherein each cycloalkyl, or heterocyclyl is unsubstituted or substituted with 1, 2, or 3 R^9, and wherein each alkyl, aryl, or heteroaryl is unsubstituted or substituted with 1, 2, or 3 R^{10};

R^4 is

(1) hydrogen, or

(2) (C_{1-3})alkyl,

when present, each R^5 is selected from

(1) hydrogen,

(2) (C_{1-3})alkyl,

(3) (C_{1-3})haloalkyl,

(4) cyano, or

(5) halogen,

when present, each R^6 is independently selected from

(1) cyano,

(2) halogen,

(3) -OC_{1-6}alkyl,

(4) (C_{3-6})cycloalkyl, optionally substituted with halogen or OH,

(5) -$(C=O)NH_2$,

(6) (C_{3-6}) cycloalkyloxy wherein the cycloalkyl is optionally substituted with halogen or OH,

(7) hydroxy,

(8) $-NR^{11}R^{11}$,

(9) -NH(C=O) (C_{1-6})alkyl,

(10) (C_{2-6})cyclic amine, optionally substituted with one or two halogen substituents,

(11) (C_{1-6})haloalkyl-,

(12) -O(C_{1-6})haloalkyl- optionally substituted with OH,

(13) -O(C_{0-3})alkyl-(C_{3-6})cycloalkyl optionally substituted with one or two halogen substituents,

(14) $-SO_2$(C_{1-6})alkyl,

(15) $-SO_2NH$(C_{1-6})alkyl,

(16) $-SC_{1-6}$alkyl,

(17) $-SC_{1-6}$haloalkyl, or

(18) (C_{1-6})alkyl,

when present, each R^7 is independently selected from

(1) (C_{1-3})alkyl,

(2) halogen,

(3) (C_{1-3})alkoxy-,

(4) (C_{1-3})haloalkyl-, or

(5) hydroxy,

when present, R^{8a} and R^{8b} are independently selected from

(1) hydrogen,

(2) (C_{1-3})alkyl, or

(3) (C_{3-7})cycloalkyl;

when present, each R^9 is independently selected from

(1) (C_{1-3})alkyl,

(2) (C_{1-3})haloalkyl-,

(3) oxo,

(4) (C_{3-6})cycloalkyl,

(5) $-N(R^{11})_2$,

(6) hydroxy,

(7) (C_{1-3})alkoxyl-,

(8) cyano,

(9) halogen,

(10) -$SO_2(C_{1-6})$alkyl,

(11) -(C_{1-6})alkyl $SO_2(C_{1-6})$alkyl,

(12) -C(O) (C_{1-3})alkyl, or

(13) $O(C_{1-3})$alkyl,

when present, R^{10} is independently selected from

(1) hydrogen,

(2) (C_{1-3})alkyl,

(3) (C_{1-3})alkoxy-,

(4) hydroxy,

(5) halogen,

(6) (C_{1-3})alkyl-S-,

(7) (C_{1-3})haloalkyl-, or


(8) $N(R^{11})_2$,


R^{11}, when present, is independently


(1) hydrogen, or


(2) (C_{1-3})alkyl.


1. In another aspect, there is provided a compound selected from:














3e







or a pharmaceutically acceptable salt thereof.

Also provided are methods of making compounds of Formula **I**, pharmaceutical compositions comprising compounds of Formula **I**, and methods of using these compounds to treat hepatic steatosis, nonalcoholic steatohepatitis (NASH), fibrosis, type-2 diabetes mellitus, obesity, hyperlipidemia, hypercholesterolemia, atherosclerosis, cognitive decline, dementia, cardiorenal diseases such as chronic kidney diseases and heart failure and related diseases and conditions, comprising administering a compound of formula **I** to a patient in need thereof.


In another aspect, there is provided a composition comprising a pharmaceutically acceptable carrier and a compound as defined herein, or a pharmaceutically acceptable salt thereof.

In another aspect, there is provided a composition for use in treating a condition selected from hepatic steatosis, nonalcoholic steatohepatitis (NASH), fibrosis, type-2 diabetes mellitus, obesity, hyperlipidemia, hypercholesterolemia, atherosclerosis, cognitive decline, dementia, cardiorenal diseases and heart failure comprising a compound as defined herein, or a pharmaceutically acceptable salt thereof, and a pharmaceutically carrier.

In another aspect, there is provided use of a compound as defined herein in the manufacture of a medicament for treating a condition selected from hepatic steatosis, nonalcoholic steatohepatitis (NASH), fibrosis, type-2 diabetes mellitus, obesity, hyperlipidemia, hypercholesterolemia, atherosclerosis, cognitive decline, dementia, cardiorenal diseases and heart failure.

DETAILED DESCRIPTION OF THE INVENTION

The present disclosure is directed to compounds having structural Formula **I**:



I

or pharmaceutically acceptable salts thereof wherein:

X, Y, and Z are independently selected from N or C(R^5);

R^1 is

(1) phenyl unsubstituted or substituted with 1, 2, or 3 R^6, or

(2) 5- or 6-membered heteroaryl containing 1, 2, 3 or 4 heteroatoms independently selected from N, O, and S, wherein the heteroaryl is unsubstituted or substituted with 1, 2, or 3 R^6, or

(3) 8- to 10- membered fused heteroaryl containing 1, 2, 3 heteroatoms independently selected from N, O, and S, wherein the heteroaryl is unsubstituted or substituted with 1, 2, or 3 R^6;


R^{2a} and R^{2b} are independently selected from

(1) hydrogen,

(2) halogen,

WHAT IS CLAIMED IS:

1. A compound of Formula I:



I , or a pharmaceutically acceptable salt thereof wherein:

X, Y, and Z are independently selected from N or C(R^5);

R^1 is

(1) phenyl unsubstituted or substituted with 1, 2, or 3 R^6,

(2) 5- or 6-membered heteroaryl containing 1, 2, 3 or 4 heteroatoms independently selected from N, O, and S, wherein the heteroaryl is unsubstituted or substituted with 1, 2, or 3 R^6, or

(3) 8- to 10- membered fused heteroaryl containing 1, 2, or 3 heteroatoms independently selected from N, O, and S, wherein the heteroaryl is unsubstituted or substituted with 1, 2, or 3 R^6;

R^{2a} and R^{2b} are independently selected from

(1) hydrogen,

(2) halogen,

(3) hydroxy,

(4) (C_{1-6})alkyl,

(5) (C_{1-6})haloalkyl,

(6) R^{2a} and R^{2b} join to form spiro(C_{3-8})cycloalkyl unsubstituted or optionally mono-substituted, disubstituted with C_{1-3}alkyl, halogen, or OH, or

(7) R^{2a} and R^{2b} join to form spiro 4- to 8- membered heterocyclyl containing 1 or 2 heteroatoms independently selected from N, O, and S wherein the heterocyclyl is unsubstituted or substituted by 1, 2, or 3 R^7;

R^3 is

(1) 4- to 7-membered heterocyclyl containing 1, 2, or 3 heteroatoms independently selected from N, O and S,

(2) 5- or 6-membered heteroaryl containing 1, 2, or 3 heteroatoms independently selected from N, O, and S,

(3) -(C_{1-6})alkyl-heteroaryl, wherein the heteroaryl is a 5- or 6-membered heteroaryl containing 1, 2, or 3 heteroatoms independently selected from N, O and S,

(4) -(C_{1-6})alkyl-aryl,

(5) -(C_{1-6})alkyl-heterocyclyl, wherein the heterocyclyl is a 3- to 6-membered ring containing 1 or 2 heteroatoms independently selected from N, O and S,

(6) -(C_{1-6})alkyl,

(7) -(C_{3-6})cycloalkyl,

(8) -(C_{1-6})hydroxyalkyl,

(9) -(C_{1-6})alkyl-$S(O)_2$-$NR^{8a}R^{8b}$, or

(10) -(C_{1-6})alkyl-$S(O)_2$-(C_{1-3})alkyl,

wherein each cycloalkyl, or heterocyclyl is unsubstituted or substituted with 1, 2, or 3 R^9, and wherein each alkyl, aryl, or heteroaryl is unsubstituted or substituted with 1, 2, or 3 R^{10};

R^4 is

(1) hydrogen, or

(2) (C_{1-3})alkyl,

~~or R^3 and R^4 combine along with the nitrogen atom to which they are attached to form a mono- or bicyclic heterocyclyl ring containing 1 or 2 heteroatoms independently selected from N, O and S, wherein the heterocyclyl ring is unsubstituted or substituted by 1, 2, or 3 R^{11},~~

when present, each R^5 is selected from

(1) hydrogen,

(2) (C_{1-3})alkyl,

(3) (C_{1-3})haloalkyl,

(4) cyano, or

(5) halogen,

when present, each R^6 is independently selected from

(1) cyano,

(2) halogen,

(3) -OC_{1-6}alkyl,

(4) (C_{3-6})cycloalkyl, optionally substituted with halogen~~,~~ or OH,

(5) -$(C=O)NH_2$,

(6) (C_{3-6}) cycloalkyloxy wherein the cycloalkyl is optionally substituted with halogen or OH,

(7) hydroxy,

(8) $-NR^{11}R^{11}$,

(9) $-NH(C=O)(C_{1-6})$alkyl,

(10) (C_{2-6})cyclic amine, optionally substituted with one or two halogen substituents,

(11) (C_{1-6})haloalkyl-,

(12) $-O(C_{1-6})$haloalkyl- optionally substituted with OH,

(13) $-O(C_{0-3})$alkyl-(C_{3-6})cycloalkyl optionally substituted with one or two halogen substituents,

(14) $-SO_2(C_{1-6})$alkyl,

(15) $-SO_2NH(C_{1-6})$alkyl,

(16) $-SC_{1-6}$alkyl,

(17) $-SC_{1-6}$haloalkyl, or

(18) (C_{1-6})alkyl,

when present, each R^7 is independently selected from

(1) (C_{1-3})alkyl,

(2) halogen,

(3) (C_{1-3})alkoxy-,

(4) (C_{1-3})haloalkyl-, or

(5) hydroxy,

when present, R^{8a} and R^{8b} are independently selected from

(1) hydrogen,

(2) (C_{1-3})alkyl, or

(3) (C_{3-7})cycloalkyl;

when present, each R^9 is independently selected from

(1) (C_{1-3})alkyl,

(2) (C_{1-3})haloalkyl-,

(3) oxo,

(4) (C_{3-6})cycloalkyl,

(5) $-N(R^{11})_2$,

(6) hydroxy,

(7) (C_{1-3})alkoxyl-,

(8) cyano,

(9) halogen,

(10) $-SO_2(C_{1-6})$alkyl,

(11) -(C_{1-6})alkyl SO_2(C_{1-6})alkyl,

(12) -C(O) (C_{1-3})alkyl, or

(13) O(C_{1-3})alkyl,

when present, R^{10} is independently selected from

(1) hydrogen,

(2) (C_{1-3})alkyl,

(3) (C_{1-3})alkoxy-,

(4) hydroxy,

(5) halogen,

(6) (C_{1-3})alkyl-S-,

(7) (C_{1-3})haloalkyl-, or

(8) $N(R^{11})_2$,

R^{11}, when present, is independently

(1) hydrogen, or

(2) (C_{1-3})alkyl.

2. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein R^1 is

a. phenyl optionally substituted with one to three substituents independently selected from halogen, hydroxy, CN, C_{1-3}alkyl, C_{1-3}haloalkyl, C_{3-6}cycloalkyl optionally substituted with halogen or OH, -OC_{1-3}alkyl, -OC_{1-3}haloalkyl optionally substituted with OH, -OC_{3-6}cycloalkyl, -SC_{1-3}alkyl, -SC_{1-3}haloalkyl, $S(O)_2C_{1-3}$alkyl, -NH(C=O)C_{1-3}alkyl, $C(O)NH_2$, $S(O)_2NHC_{1-3}$alkyl, $N(R^{11})_2$, or azetidinyl optionally substituted with one or two halogen substituents;

b. a 6 membered heteroaryl containing one or two nitrogen atoms substituted with one or two substituents independently selected from halogen, hydroxy, C_{1-3}alkyl, C_{1-3}haloalkyl, C_{3-6}cycloalkyl, -OC_{1-6}alkyl, ~~-OC_{1-3}alkyl,~~ -OC_{1-3}haloalkyl optionally substituted with OH, -OC_{0-3}alkyl-C_{3-6}cycloalkyl optionally substituted with 1-2 halogens substituents, azetidinyl optionally substituted with 1-2 halogens substituents, CN, -SC_{1-3}alkyl, or -SC_{1-3}haloalkyl;

~~c. a 5 membered heteroaryl containing one to four nitrogen atoms or heteroatoms independently selected from N, O, and S optionally substituted with one to two substituents independently selected from halogen, (C_{1-3})alkyl, (C_{3-6})cycloalkyl, (C_{1-3})haloalkyl-, -OH, OC_{1-3}alkyl, OC_{0-3}alkyl-C_{3-6}cycloalkyl optionally substituted with 1-2 halogens, O(C_{1-3})haloalkyl-, O(C_{1-3})haloalkyl-OH, azetidinyl optionally substituted with 1-2 halogens;~~ or

~~d.~~c. 8- to 10- membered fused heteroaryl containing 1, 2, or 3 heteroatoms independently selected from N, O, and S, wherein the heteroaryl is unsubstituted or substituted with halogen, (C_{1-3})alkyl, (C_{3-6})cycloalkyl, (C_{1-3})haloalkyl-, OH or OC_{1-3}alkyl.

3. The compound of any one of claims 1-2, or a pharmaceutically acceptable salt thereof, wherein R^1 is

a. phenyl substituted with a substituent selected from: halogen, hydroxy, C_{1-3}alkyl, C_{1-3}haloalkyl, C_{3-6}cycloalkyl, -OC_{1-3}alkyl, -OC_{1-3}haloalkyl, -O-cyclopropyl optionally substituted with halogen or hydroxy, -SC_{1-3}alkyl, -SC_{1-3}haloalkyl, $S(O)_2NHCH_3$, $S(O)_2C_{1-3}$alkyl, -$NH(C{=}O)C_{1-3}$alkyl, CN, azetidinyl optionally substituted with one or two fluoro substituents, $C(O)NH_2$, $N(CH_3)_2$, and wherein the phenyl is optionally further substituted with 1 or 2 fluorine atoms;

b. a 6 membered heteroaryl containing one or two nitrogen atoms substituted with one or two substituents selected from: halogen, C_{1-3}alkyl, C_{1-3}haloalkyl, -OC_{1-3}~~alkyl~~$_6$alkyl, -OC_{1-3}haloalkyl optionally substituted with hydroxy, -O-cyclopropyl optionally substituted with halogen~~ or hydroxy~~, -O-C_{1-3}alkyl-C_{3-6}cycloalkyl optionally substituted with one or two fluoro substituents, -SC_{1-3}alkyl, -SC_{1-3}haloalkyl, and azetidinyl optionally substituted with one or two fluoro substituents,~~ halogen, -OC_{1-3}alkyl-OH, -OC_{1-3}haloalkyl-OH, and wherein the 6-membered heteroaryl is optionally further substituted with 1 or 2 fluorine atoms or CH_3~~;

~~c. 5 membered heteroaryl containing one to four nitrogen atoms or heteroatoms independently selected from N, O, and S optionally substituted with one to two substituents independently selected from with halogen, (C_{1-3})alkyl, (C_{3-6})cycloalkyl, (C_{1-6})haloalkyl-, -OH, OC_{1-6}alkyl, OC_{0-3}alkyl-C_{3-}~~


~~6~~cycloalkyl optionally substituted with 1-2 halogens, O(C_{1-3})haloalkyl , O(C_{1-3})haloalkyl-OH, azetidinyl optionally substituted with 1-2 fluoro substituents ;


or

~~d.~~c. 9 or 10- membered fused heteroaryl containing one or two heteroatoms independently selected from nitrogen or oxygen, optionally substituted with methyl.

4. The compound of any one of claims 1-3, or a pharmaceutically acceptable salt thereof, wherein R^1 is a phenyl substituted with substituent selected from -OH, -CH_3, -CF_2CH_3, -$OCHF_2$, -OCH_2CH_3, -$OCH(CH_3)_2$, -OCF_2CH_3, -OCF_2CHF_2, -OCH_2CHF_2, -OCF_3, O-cyclopropyl, cyclopropyl, -$SCHF_2$, CN, F, $S(O)_2NHCH_3$, $C(O)NH_2$, $S(O)_2CH_3$, $N(CH_3)_2$, -$NH(C{=}O)CH_3$, or azetidinyl ~~or 3,3-difluoroazetidinyl wherein the phenyl is optionally further substituted with 1 or 2 fluorine atoms~~.

5. The compound of any one of claims 1-3, or a pharmaceutically acceptable salt thereof, wherein R^1 is a pyridinyl, substituted with one or two substituents independently selected from F, ~~OH,~~ -CH_3, -CF_2CH_3, -$OCH(CH_3)_2$, -$OCHF_2$, -OCH_2CH_3, -OCF_2CH_3, -OCF_2CHF_2, -$OCH_2CH(CH_3)_2$, -OCH_2CHF_2, -OCH_2CF_3, -OCF_3, ~~cyclopropyl,~~ O-cyclopropyl, -O-CH_2-cyclopropyl optionally substituted with 1 or 2 F, -O-CH_2-cyclobutyl optionally substituted with 2 F, -$OCH_2CF_2CH_3$, -$OCH_2CF_2CHF_2$, -OCF_2CH_2OH, azetidinyl, 3,3-difluoroazetidinyl, or -$SCHF_2$.

6. The compound of any one of claims 1-3, or a pharmaceutically acceptable salt thereof, wherein R^1 is 



~~6.~~7. The compound of any one of claims 1-~~5~~6, or a pharmaceutically acceptable salt thereof, wherein R^{2a} and R^{2b} are selected from one of the following:

a. R^{2a} and R^{2b} are hydrogen,

b. R^{2a} is hydrogen and R^{2b} is (C_{1-6})alkyl, or R^{2a} is (C_{1-6})alkyl and R^{2b} is hydrogen,

c. R^{2a} is halogen and R^{2b} is (C_{1-6})alkyl, or R^{2a} is (C_{1-6})alkyl and R^{2b} is halogen,

d. R^{2a} is hydroxy and R^{2b} and (C_{1-6})alkyl, or R^{2a} is (C_{1-6})alkyl and R^{2b} is hydroxy,

e. R^{2a} is hydroxy and R^{2b} and (C_{1-6})haloalkyl, or R^{2a} is (C_{1-6})haloalkyl and R^{2b} is hydroxy,

f. R^{2a} and R^{2b} are each independently selected from (C_{1-6})alkyl,

g. R^{2a} and R^{2b} join to form spiro 4- to 8- membered heterocyclyl containing 1 or 2 heteroatoms independently selected from N, O and S wherein the heterocyclyl is unsubstituted or substituted by 1, 2, or 3 R^7, or

h. R^{2a} and R^{2b} join to form spiro(C_{3-8})cycloalkyl unsubstituted or optionally mono-substituted, or disubstituted with C_{1-6}alkyl, halogen, or OH.

~~7.~~8. The compound of any one of claims 1-~~6~~7, or a pharmaceutically acceptable salt thereof, wherein R^{2a} and R^{2b} are independently selected from hydrogen, CH_3, OH, CF_3, $CH(CH_3)_2$, or CH_2CH_3~~H, and C_{1-3}alkyl, or together form a spiro C_{1-6}cycloalkyl~~.

~~8.~~9. The compound of any one of claims 1-~~7~~8, or a pharmaceutically acceptable salt thereof, wherein R^3 is selected from

(a) 4- to 7-membered heterocyclyl containing 1, 2 or 3 heteroatoms independently selected from N, O, and S,

(b) 5- or 6-membered heteroaryl containing 1, 2 or 3 heteroatoms independently selected from N, O, and S,

(c) -(C_{1-6})alkyl-heteroaryl, wherein the heteroaryl is a 5- or 6-membered heteroaryl containing 1, 2 or 3 heteroatoms independently selected from N, O and S,

(d) -(C_{1-6})alkyl-aryl,

~~(e) -(C_{1-6})-heterocyclyl, wherein the heterocyclyl is a 3- to 6-membered ring containing 1 or 2 heteroatoms independently selected from N, O and S,~~

~~(f)~~(e) -(C_{1-6})alkyl,

~~(g)~~(f) -(C_{3-6})cycloalkyl,

~~(h)~~(g) (C_{1-6})hydroxyalkyl,

~~(i)~~(h) -(C_{1-6})alkyl-$S(O)_2$-$NR^{8a}R^{8b}$, ~~or~~

~~(j)~~(i) -(C_{1-6})alkyl-$S(O)_2$-(C_{1-3})alkyl, or

~~(k)~~(j) -(C_{1-6})alkyl-heterocyclyl, wherein the heterocyclyl is a 5- membered heterocyclyl containing 1, 2 or 3 heteroatoms independently selected from N, O, and S,

wherein each aryl, heteroaryl, cycloalkyl, or heterocyclyl is unsubstituted or substituted with 1, 2, or 3 R^9, and wherein each alkyl, aryl, or heteroaryl is unsubstituted or substituted with 1, 2, or 3 R^{10}.

~~9.~~10. The compound of any one of claims 1-~~8~~9, or a pharmaceutically acceptable salt thereof, wherein R^3 is

(~~1~~a) 4- to 6-membered heterocyclyl containing 1, 2 or 3 heteroatoms independently selected from N, O and S,

(~~2~~b) -(C_{3-6})cycloalkyl,

(~~3~~c) -(C_{1-6})hydroxyalkyl,

(~~4~~d) -(C_{1-6})alkyl-$S(O)_2$-$NR^{8a}R^{8b}$,

(~~5~~e) -(C_{1-6})alkyl-$S(O)_2$-(C_{1-3})alkyl,


(~~6~~f) (C_{1-6})alkyl-heterocyclyl, wherein the heterocyclyl is a 5-membered heterocyclyl containing one oxygen~~1 O~~ ~~heter~~oatom,


(~~7~~g) 5- to 6-membered heteroaryl containing 1, 2, or 3 heteroatoms independently selected from N, O and S, or


(~~8~~h) (C_{1-6})alkyl-heteroaryl, wherein the heteroaryl is a 5-membered heteroaryl containing 2 N heteroatoms,











wherein each cycloalkyl, heteroaryl or heterocyclyl is unsubstituted or substituted with 1, 2, or 3 R^9, and wherein each alkyl is unsubstituted or substituted with 1, 2, or 3 R^{10}.


11. The compound of any one of claims 1-9, or a pharmaceutically acceptable salt thereof, wherein R^3 is










[10.]12. The compound of any one of claims 1-[9]11, or a pharmaceutically acceptable salt thereof, wherein R^3 is .

[11.]13. The compound of any one of claims 1-[9]11, or a pharmaceutically acceptable salt thereof, wherein R^3 is .

[12.]14. The compound of any one of claims 1-[9]11, or a pharmaceutically acceptable salt thereof, wherein R^3 is .

[13.]15. The compound of any one of claims 1-[13]15, or a pharmaceutically acceptable salt thereof, wherein R^3 is .

[14.]16. The compound of any one of claims 1-[13]15, or a pharmaceutically acceptable salt thereof, wherein R^4 is H.

[15.]17. The compound of any one of claims 1-[14]16, or a pharmaceutically acceptable salt thereof, wherein R^5 is H, F, Cl, or CN.

[16.]18. The compound of any one of claims 1-[15]17, or a pharmaceutically acceptable salt

thereof, wherein R^6 is halogen, hydroxy, CN, -C_{1-6}alkyl, -C_{1-6}haloalkyl, -C_{3-6}cycloalkyl optionally substituted with halogen or OH, -OC_{1-6}alkyl, -OC_{1-6}haloalkyl optionally substituted with OH, -$O(C_{1-3})$alkyl-(C_{3-6})cycloalkyl optionally substituted with one or two halogen substituents, -OC_{3-6}cycloalkyl, -$SO_2NH(C_{1-6})$alkyl, -$S(O)_2C_{1-6}$alkyl, -S-C_{1-6}alkyl, -SC_{1-6}haloalkyl, ~~or~~ $NH(C{=}O)C_{1-3}$alkyl, (C_{2-6})cyclic amine optionally substituted with one or two halogen substituents, or $N((C_{1-3})alkyl)_2$, ~~-O(C_{3-6})cycloalkyl~~.

~~17.~~19. The compound of any one of claims 1-~~16~~18, or a pharmaceutically acceptable salt thereof, wherein R^6 is F, CN, OH, -CH_3, -CF_2CH_3, -OCF_2CH_3, -$OCHF_2$, -OCF_3, OCH_2CF_3, -OCH_2CH_3, $OCH(CH_3)_2$, -OCF_2CHF_2, -OCH_2CHF_2, -$OCHF_2CH_3$, $OCH_2CF_2CH_3$, $OCH_2CH(CH_3)_2$, $OCH_2CF_2CHF_2$, -cyclopropyl, -O-cyclopropyl, OCH_2-cyclopropyl optionally substituted with 1 or 2 F, OCH_2-cyclobutyl optionally substituted with 1 or 2 F, azetidine optionally substituted with 1 or 2 F, -$SCHF_2$, $S(O)_2CH_3$, $S(O)_2NHCH_3$, ~~C(O)NH_2,~~ $N(CH_3)_2$, OCF_2CH_2OH, or -$NH(C{=}O)C_{1-3}$alkyl.

~~18.~~20. The compound of any one of claims 1-~~17~~19, or a pharmaceutically acceptable salt thereof, wherein R^{8a} and R^{8b} are independently selected from hydrogen and cyclohexyl.

~~19.~~21. The compound of any one of claims 1-~~18~~20, or a pharmaceutically acceptable salt thereof, wherein R^9 is =O, -OH, halogen, OC_{1-3}alkyl, C_{1-3}alkyl, C_{1-3}haloalkyl, C_{1-3}alkylOH, -$SO_2(C_{1-3})$alkyl, ~~or~~ -$C_{(1-3)}$alkyl$SO_2(C_{1-3})$alkyl, or $C(O)C_{1-3}$alkyl.

~~20.~~22. The compound of any one of claims 1-~~19~~21, or a pharmaceutically acceptable salt thereof, wherein R^{10} is hydrogen, OH, CH_3, CH_2CH_3, F, CF_3, or CH_2OH ~~or $CH_2SO_2CH_3$~~.

~~21.~~23. The compound of any one of claims 1-~~20~~22, or a pharmaceutically acceptable salt thereof, wherein X is N, Y is $C(R^5)$, and Z is $C(R^5)$.


~~22.~~24. The compound of any one of claims 1-~~20~~22, or a pharmaceutically acceptable salt


thereof, wherein X is C(R^5), Y is N, and Z is C(R^5).


~~23.~~25. The compound of any one of claims 1-~~20~~22, or a pharmaceutically acceptable salt thereof, wherein X, Y, and Z are each C(R^5).






































~~24.~~26. The compound of any one of claims 1-~~20~~22, or a pharmaceutically acceptable salt thereof, wherein X is N, Y is N and Z is C(R^5).






























~~25.~~27. A compound selected from:








,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,,

,



,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,



or a pharmaceutically acceptable salt thereof.

~~26.~~28. The compound of claim 1, or a pharmaceutically acceptable salt thereof, which is:

1-(3-(difluoromethoxy)phenyl)-3,3-dimethyl-*N*-(3-methyl-1,1-dioxidothietan-3-yl)-2-oxoindoline-5-carboxamide,

1-(3-(difluoromethoxy)phenyl)-3-isopropyl-*N*-(3-methyl-1,1-dioxidothietan-3-yl)-2-oxoindoline-5-carboxamide,

1'-(3-(difluoromethoxy)phenyl)-*N*-(3-methyl-1,1-dioxidothietan-3-yl)-2'-oxospiro[cyclobutane-1,3'-indoline]-5'-carboxamide,

(*R*)-1-(3-(difluoromethoxy)phenyl)-3-ethyl-3-methyl-*N*-(3-methyl-1,1-dioxidothietan-3-yl)-2-oxoindoline-5-carboxamide,

(*S*)-1-(3-(difluoromethoxy)phenyl)-3-ethyl-3-methyl-*N*-(3-methyl-1,1-dioxidothietan-3-yl)-2-oxoindoline-5-carboxamide,

(*R*)-1-(3-(difluoromethoxy)phenyl)-3-ethyl-3-methyl-*N*-((*S*)-3-methyl-1,1-dioxidotetrahydrothiophen-3-yl)-2-oxoindoline-5-carboxamide,

(*S*)-1-(3-(difluoromethoxy)phenyl)-3-ethyl-3-methyl-*N*-((*S*)-3-methyl-1,1-dioxidotetrahydrothiophen-3-yl)-2-oxoindoline-5-carboxamide,

1-[3-(difluoromethoxy)phenyl]-3,3-dimethyl-*N*-(4-methyl-1,1-dioxo-thian-4-yl)-2-oxo-indoline-5-carboxamide,

1-[3-(difluoromethoxy)phenyl]-3,3-dimethyl-*N*-[(3*R*)-(3-methyl-1,1-dioxo-thiolan-3-yl)]-2-oxo-indoline-5-carboxamide,

1-[3-(difluoromethoxy)phenyl]-*N*-[(1*S*,2*R*)-2-hydroxycyclopentyl]-3,3-dimethyl-2-oxo-indoline-

5-carboxamide,
3,3-dimethyl-*N*-[(3*S*)-3-methyl-1,1-dioxo-thiolan-3-yl]-2-oxo-1-[3-(trifluoromethoxy)phenyl]indoline-5-carboxamide,
3,3-dimethyl-*N*-[(3*R*)-3-methyl-1,1-dioxo-thiolan-3-yl]-2-oxo-1-[3-(trifluoromethoxy)phenyl]indoline-5-carboxamide,
3,3-dimethyl-*N*-(3-methyl-1,1-dioxo-thietan-3-yl)-2-oxo-1-[3-(trifluoromethoxy)phenyl]indoline-5-carboxamide,
1-[3-(difluoromethoxy)phenyl]-*N*-[4-(hydroxymethyl)tetrahydropyran-4-yl]-3,3-dimethyl-2-oxo-indoline-5-carboxamide,
1-[5-(difluoromethoxy)-2-fluoro-phenyl]-3,3-dimethyl-*N*-[(3*R*)-3-methyl-1,1-dioxo-thiolan-3-yl]-2-oxo-indoline-5-carboxamide,
1-[5-(difluoromethoxy)-2-fluoro-phenyl]-3,3-dimethyl-*N*-[(3*S*)-3-methyl-1,1-dioxo-thiolan-3-yl]-2-oxo-indoline-5-carboxamide,
1-[5-(difluoromethoxy)-2-fluoro-phenyl]-3,3-dimethyl-*N*-(4-methyl-1,1-dioxo-thian-4-yl)-2-oxo-indoline-5-carboxamide,
1-[3-(2,2-difluoroethoxy)phenyl]-3,3-dimethyl-*N*-[(3R)-3-methyl-1,1-dioxo-thiolan-3-yl]-2-oxo-indoline-5-carboxamide,
1-[3-(2,2-difluoroethoxy)phenyl]-3,3-dimethyl-*N*-[(3*S*)-3-methyl-1,1-dioxo-thiolan-3-yl]-2-oxo-indoline-5-carboxamide,
1-[3-(2,2-difluoroethoxy)phenyl]-3,3-dimethyl-*N*-(4-methyl-1,1-dioxo-thian-4-yl)-2-oxo-indoline-5-carboxamide,
3,3-dimethyl-N-(3-methyl-1,1-dioxo-thietan-3-yl)-2-oxo-1-[5-(1,1,2,2-tetrafluoroethoxy)-3-pyridyl]indoline-5-carboxamide,
3,3-dimethyl-*N*-[(3*R*)-3-methyl-1,1-dioxo-thiolan-3-yl]-2-oxo-1-[5-(1,1,2,2-tetrafluoroethoxy)-3-pyridyl]indoline-5-carboxamide,
3,3-dimethyl-*N*-[(3*S*)-3-methyl-1,1-dioxo-thiolan-3-yl]-2-oxo-1-[5-(1,1,2,2-tetrafluoroethoxy)-3-pyridyl]indoline-5-carboxamide,
3,3-dimethyl-*N*-(4-methyl-1,1-dioxo-thian-4-yl)-2-oxo-1-[5-(1,1,2,2-tetrafluoroethoxy)-3-pyridyl]indoline-5-carboxamide,
(*R*)-1-(3-(difluoromethoxy)phenyl)-*N*-(4-hydroxy-2-methylpentan-2-yl)-3,3-dimethyl-2-oxoindoline-5-carboxamide,
(*S*)-1-(3-(difluoromethoxy)phenyl)-*N*-(4-hydroxy-2-methylpentan-2-yl)-3,3-dimethyl-2-oxoindoline-5-carboxamide,

1-(2-ethoxy-5-fluoro-4-pyridyl)-3,3-dimethyl-*N*-(3-methyl-1,1-dioxo-thietan-3-yl)-2-oxo-indoline-5-carboxamide,

1-(2-ethoxy-5-fluoro-4-pyridyl)-3,3-dimethyl-*N*-[(3*R*)-3-methyl-1,1-dioxo-thiolan-3-yl]-2-oxo-indoline-5-carboxamide,

1-(2-ethoxy-5-fluoro-4-pyridyl)-3,3-dimethyl-*N*-[(3*S*)-3-methyl-1,1-dioxo-thiolan-3-yl]-2-oxo-indoline-5-carboxamide,

1-[2-(2,2-difluoroethoxy)pyrimidin-4-yl]-3,3-dimethyl-*N*-(3-methyl-1,1-dioxo-thietan-3-yl)-2-oxo-indoline-5-carboxamide,

3,3-dimethyl-*N*-(3-methyl-1,1-dioxo-thietan-3-yl)-2-oxo-1-(3-quinolyl)indoline-5-carboxamide,

N-[2-(cyclohexylsulfamoyl)ethyl]-1-[3-(difluoromethoxy)phenyl]-3,3-dimethyl-2-oxo-indoline-5-carboxamide,

1-[3-(difluoromethoxy)phenyl]-3,3-dimethyl-*N*-[1-(methylsulfonylmethyl)cyclohexyl]-2-oxo-indoline-5-carboxamide,

1-[3-(difluoromethoxy)phenyl]-*N*-(3-ethyl-1,1-dioxo-thietan-3-yl)-3,3-dimethyl-2-oxo-indoline-5-carboxamide,

1-[3-(cyclopropoxy)phenyl]-3,3-dimethyl-*N*-(3-methyl-1,1-dioxo-thietan-3-yl)-2-oxo-indoline-5-carboxamide,

1-[3-(cyclopropoxy)phenyl]-3,3-dimethyl-*N*-[(3*R*)-3-methyl-1,1-dioxo-thiolan-3-yl]-2-oxo-indoline-5-carboxamide,

1-[3-(cyclopropoxy)phenyl]-3,3-dimethyl-*N*-[(3*S*)-3-methyl-1,1-dioxo-thiolan-3-yl]-2-oxo-indoline-5-carboxamide,

1-[3-(cyclopropoxy)phenyl]-3,3-dimethyl-*N*-(4-methyl-1,1-dioxo-thian-4-yl)-2-oxo-indoline-5-carboxamide,

3,3-dimethyl-*N*-(4-methyl-1,1-dioxo-thian-4-yl)-2-oxo-1-[3-(trifluoromethoxy)phenyl]indoline-5-carboxamide,

1-[3-(difluoromethoxy)phenyl]-3,3-dimethyl-*N*-[(3*S*)-(3-methyl-1,1-dioxo-thiolan-3-yl)]-2-oxo-indoline-5-carboxamide,

1-[3-(difluoromethoxy)phenyl]-*N*-(3,3-difluoro-1-methyl-cyclobutyl)-3,3-dimethyl-2-oxo-indoline-5-carboxamide,

3,3-dimethyl-*N*-(3-methyl-1,1-dioxo-thietan-3-yl)-2-oxo-1-[5-(trifluoromethoxy)-3-pyridyl]indoline-5-carboxamide,

1-[5-(difluoromethoxy)-3-pyridyl]-3,3-dimethyl-*N*-(3-methyl-1,1-dioxo-thietan-3-yl)-2-oxo-indoline-5-carboxamide,

1-(5-ethoxy-3-pyridyl)-3,3-dimethyl-*N*-(3-methyl-1,1-dioxo-thietan-3-yl)-2-oxo-indoline-5-carboxamide,
1-[5-(2,2-difluoroethoxy)-3-pyridyl]-3,3-dimethyl-*N*-(3-methyl-1,1-dioxo-thietan-3-yl)-2-oxo-indoline-5-carboxamide,
1-[5-(difluoromethylsulfanyl)-3-pyridyl]-3,3-dimethyl-*N*-(3-methyl-1,1-dioxo-thietan-3-yl)-2-oxo-indoline-5-carboxamide,
1-[2-(2,2-difluoroethoxy)-5-fluoro-4-pyridyl]-3,3-dimethyl-*N*-(3-methyl-1,1-dioxo-thietan-3-yl)-2-oxo-indoline-5-carboxamide,
1-[5-(2,2-difluoroethoxy)-2,3-difluoro-phenyl]-3,3-dimethyl-*N*-(3-methyl-1,1-dioxo-thietan-3-yl)-2-oxo-indoline-5-carboxamide,
1-[5-(2,2-difluoroethoxy)-2-fluoro-phenyl]-3,3-dimethyl-*N*-(3-methyl-1,1-dioxo-thietan-3-yl)-2-oxo-indoline-5-carboxamide,
1-[6-(2,2-difluoroethoxy)pyrazin-2-yl]-3,3-dimethyl-*N*-(3-methyl-1,1-dioxo-thietan-3-yl)-2-oxo-indoline-5-carboxamide,
1-[3-(2,2-difluoroethoxy)phenyl]-3,3-dimethyl-*N*-(3-methyl-1,1-dioxo-thietan-3-yl)-2-oxo-indoline-5-carboxamide,
1-[5-(difluoromethylsulfanyl)-2-fluoro-phenyl]-3,3-dimethyl-*N*-(3-methyl-1,1-dioxo-thietan-3-yl)-2-oxo-indoline-5-carboxamide,
1-[5-(difluoromethoxy)-2-fluoro-phenyl]-3,3-dimethyl-*N*-(3-methyl-1,1-dioxo-thietan-3-yl)-2-oxo-indoline-5-carboxamide,
1-[5-(1,1-difluoroethyl)-3-pyridyl]-3,3-dimethyl-*N*-(3-methyl-1,1-dioxo-thietan-3-yl)-2-oxo-indoline-5-carboxamide,
1-[5-(1,1-difluoroethoxy)-3-pyridyl]-3,3-dimethyl-*N*-(3-methyl-1,1-dioxo-thietan-3-yl)-2-oxo-indoline-5-carboxamide,
1-[5-(2,2-difluoroethoxy)-2-methyl-3-pyridyl]-3,3-dimethyl-*N*-(3-methyl-1,1-dioxo-thietan-3-yl)-2-oxo-indoline-5-carboxamide,
(*R*)-1'-(3-(difluoromethoxy)phenyl)-*N*-(3-methyl-1,1-dioxidotetrahydrothiophen-3-yl)-2'-oxospiro[cyclopropane-1,3'-indoline]-5'-carboxamide,
1-[3-(difluoromethoxy)phenyl]-7-fluoro-3,3-dimethyl-*N*-[(3*R*)-3-methyl-1,1-dioxo-thiolan-3-yl]-2-oxo-indoline-5-carboxamide,
1-[3-(difluoromethoxy)phenyl]-7-fluoro-3,3-dimethyl-*N*-(4-methyl-1,1-dioxo-thian-4-yl)-2-oxo-indoline-5-carboxamide,
1-[3-(difluoromethoxy)phenyl]-7-fluoro-3,3-dimethyl-*N*-(3-methyl-1,1-dioxo-thietan-3-yl)-2-

oxo-indoline-5-carboxamide,
1'-[3-(difluoromethoxy)phenyl]-*N*-[(3*R*)-3-methyl-1,1-dioxo-thiolan-3-yl]-2'-oxo-spiro[cyclopentane-1,3'-indoline]-5'-carboxamide,
1'-[3-(difluoromethoxy)phenyl]-*N*-(4-methyl-1,1-dioxo-thian-4-yl)-2'-oxo-spiro[cyclopentane-1,3'-indoline]-5'-carboxamide,
1'-[3-(difluoromethoxy)phenyl]-*N*-(3-methyl-1,1-dioxo-thietan-3-yl)-2'-oxo-spiro[cyclopentane-1,3'-indoline]-5'-carboxamide,
1'-[3-(difluoromethoxy)phenyl]-*N*-(3-methyl-1,1-dioxo-thietan-3-yl)-2'-oxo-spiro[cyclopropane-1,3'-indoline]-5'-carboxamide,
1'-[3-(difluoromethoxy)phenyl]-*N*-(4-methyl-1,1-dioxo-thian-4-yl)-2'-oxo-spiro[cyclopropane-1,3'-indoline]-5'-carboxamide,
1-(3-(difluoromethoxy)phenyl)-3,3-dimethyl-*N*-((3*S*,4*R*)-4-methyl-1,1-dioxidotetrahydrothiophen-3-yl)-2-oxoindoline-5-carboxamide,
1-(3-(difluoromethoxy)phenyl)-3,3-dimethyl-*N*-((3*R*,4*R*)-4-methyl-1,1-dioxidotetrahydrothiophen-3-yl)-2-oxoindoline-5-carboxamide,
1-(3-(difluoromethoxy)phenyl)-3,3-dimethyl-*N*-((3*S*,4*S*)-4-methyl-1,1-dioxidotetrahydrothiophen-3-yl)-2-oxoindoline-5-carboxamide,
1-(3-(difluoromethoxy)phenyl)-3,3-dimethyl-*N*-((3*R*,4*S*)-4-methyl-1,1-dioxidotetrahydrothiophen-3-yl)-2-oxoindoline-5-carboxamide,
1-(3-(difluoromethoxy)phenyl)-3,3-dimethyl-*N*-((3*S*,5*R*)-5-methyl-1,1-dioxidotetrahydrothiophen-3-yl)-2-oxoindoline-5-carboxamide,
1-(3-(difluoromethoxy)phenyl)-3,3-dimethyl-N-((3*R*,5*R*)-5-methyl-1,1-dioxidotetrahydrothiophen-3-yl)-2-oxoindoline-5-carboxamide,
1-(3-(difluoromethoxy)phenyl)-3,3-dimethyl-N-((3*S*,5*S*)-5-methyl-1,1-dioxidotetrahydrothiophen-3-yl)-2-oxoindoline-5-carboxamide,
1-(3-(difluoromethoxy)phenyl)-3,3-dimethyl-*N*-((3*R*,5*S*)-5-methyl-1,1-dioxidotetrahydrothiophen-3-yl)-2-oxoindoline-5-carboxamide,
1-(3-(difluoromethoxy)phenyl)-3,3-dimethyl-*N*-((1*S*,2*R*)-2-(methylsulfonyl)cyclopentyl)-2-oxoindoline-5-carboxamide,
1-(3-(difluoromethoxy)phenyl)-3,3-dimethyl-*N*-((1*R*,2*R*)-2-(methylsulfonyl)cyclopentyl)-2-oxoindoline-5-carboxamide,
1-(3-(difluoromethoxy)phenyl)-3,3-dimethyl-*N*-((1*S*,2*S*)-2-(methylsulfonyl)cyclopentyl)-2-oxoindoline-5-carboxamide,

1-(3-(difluoromethoxy)phenyl)-3,3-dimethyl-*N*-((1*R*,2*S*)-2-(methylsulfonyl)cyclopentyl)-2-oxoindoline-5-carboxamide,

1-[3-(difluoromethoxy)phenyl]-*N*-(1,1-dimethyl-2-methylsulfonyl-ethyl)-3,3-dimethyl-2-oxo-indoline-5-carboxamide,

1-[2-fluoro-5-(trifluoromethoxy)phenyl]-3,3-dimethyl-*N*-(3-methyl-1,1-dioxo-thietan-3-yl)-2-oxo-indoline-5-carboxamide,

1-[2-fluoro-5-(trifluoromethoxy)phenyl]-3,3-dimethyl-*N*-[(3R)-3-methyl-1,1-dioxo-thiolan-3-yl]-2-oxo-indoline-5-carboxamide,

1-[2-fluoro-5-(trifluoromethoxy)phenyl]-3,3-dimethyl-*N*-[(3S)-3-methyl-1,1-dioxo-thiolan-3-yl]-2-oxo-indoline-5-carboxamide,

1-[2-fluoro-5-(trifluoromethoxy)phenyl]-3,3-dimethyl-*N*-(4-methyl-1,1-dioxo-thian-4-yl)-2-oxo-indoline-5-carboxamide,

7-fluoro-3,3-dimethyl-N-(4-methyl-1,1-dioxo-thian-4-yl)-2-oxo-1-[5-(trifluoromethoxy)-3-pyridyl]indoline-5-carboxamide,

1-[5-(difluoromethoxy)-2-fluoro-phenyl]-7-fluoro-3,3-dimethyl-*N*-(3-methyl-1,1-dioxo-thietan-3-yl)-2-oxo-indoline-5-carboxamide,

1-[5-(difluoromethoxy)-2-fluoro-phenyl]-7-fluoro-3,3-dimethyl-*N*-[(3*R*)-3-methyl-1,1-dioxo-thiolan-3-yl]-2-oxo-indoline-5-carboxamide,

1-[5-(difluoromethoxy)-2-fluoro-phenyl]-7-fluoro-3,3-dimethyl-*N*-[(3*S*)-3-methyl-1,1-dioxo-thiolan-3-yl]-2-oxo-indoline-5-carboxamide,

1-[5-(difluoromethoxy)-2-fluoro-phenyl]-7-fluoro-3,3-dimethyl-*N*-(4-methyl-1,1-dioxo-thian-4-yl)-2-oxo-indoline-5-carboxamide,

1-(2-ethoxy-5-fluoro-4-pyridyl)-7-fluoro-3,3-dimethyl-*N*-(3-methyl-1,1-dioxo-thietan-3-yl)-2-oxo-indoline-5-carboxamide,

1-(2-ethoxy-5-fluoro-4-pyridyl)-7-fluoro-3,3-dimethyl-*N*-[(3*R*)-3-methyl-1,1-dioxo-thiolan-3-yl]-2-oxo-indoline-5-carboxamide,

1-(2-ethoxy-5-fluoro-4-pyridyl)-7-fluoro-3,3-dimethyl-*N*-[(3*S*)-3-methyl-1,1-dioxo-thiolan-3-yl]-2-oxo-indoline-5-carboxamide,

1-(2-ethoxy-5-fluoro-4-pyridyl)-7-fluoro-3,3-dimethyl-*N*-(4-methyl-1,1-dioxo-thian-4-yl)-2-oxo-indoline-5-carboxamide,

1-[5-(difluoromethoxy)-2-fluoro-phenyl]-3,3-dimethyl-*N*-(3-methyl-1,1-dioxo-thietan-3-yl)-2-oxo-pyrrolo[2,3-*b*]pyridine-5-carboxamide,

1-[5-(difluoromethoxy)-2-fluoro-phenyl]-3,3-dimethyl-*N*-[(3*R*)-3-methyl-1,1-dioxo-thiolan-3-

yl]-2-oxo-pyrrolo[2,3-*b*]pyridine-5-carboxamide,
1-[5-(difluoromethoxy)-2-fluoro-phenyl]-3,3-dimethyl-*N*-[(3*S*)-3-methyl-1,1-dioxo-thiolan-3-yl]-2-oxo-pyrrolo[2,3-*b*]pyridine-5-carboxamide,
1-[5-(difluoromethoxy)-2-fluoro-phenyl]-3,3-dimethyl-*N*-(4-methyl-1,1-dioxo-thian-4-yl)-2-oxo-pyrrolo[2,3-*b*]pyridine-5-carboxamide,
7-fluoro-3,3-dimethyl-*N*-(3-methyl-1,1-dioxo-thietan-3-yl)-2-oxo-1-[5-(trifluoromethoxy)-3-pyridyl]indoline-5-carboxamide,
7-fluoro-3,3-dimethyl-*N*-[(3*R*)-3-methyl-1,1-dioxo-thiolan-3-yl]-2-oxo-1-[5-(trifluoromethoxy)-3-pyridyl]indoline-5-carboxamide,
7-fluoro-3,3-dimethyl-*N*-[(3*S*)-3-methyl-1,1-dioxo-thiolan-3-yl]-2-oxo-1-[5-(trifluoromethoxy)-3-pyridyl]indoline-5-carboxamide,
1-[3-(difluoromethoxy)phenyl]-3,3-dimethyl-*N*-(4-methyl-1,1-dioxo-thian-4-yl)-2-oxo-pyrrolo[2,3-*b*]pyridine-5-carboxamide,
1-[3-(difluoromethoxy)phenyl]-3,3-dimethyl-*N*-(3-methyl-1,1-dioxo-thietan-3-yl)-2-oxo-pyrrolo[2,3-*b*]pyridine-5-carboxamide,
1-[3-(difluoromethoxy)phenyl]-3,3-dimethyl-*N*-[(3*R*)-3-methyl-1,1-dioxo-thiolan-3-yl]-2-oxo-pyrrolo[2,3-*b*]pyridine-5-carboxamide,
1-[3-(difluoromethoxy)phenyl]-3,3-dimethyl-*N*-[(3*S*)-3-methyl-1,1-dioxo-thiolan-3-yl]-2-oxo-pyrrolo[2,3-*b*]pyridine-5-carboxamide.
3,3-dimethyl-*N*-(3-methyl-1,1-dioxidothietan-3-yl)-1-(2-methylbenzo[d]oxazol-6-yl)-2-oxoindoline-5-carboxamide,
1-[6-(2,2-difluoroethoxy)pyridazin-4-yl]-3,3-dimethyl-*N*-(3-methyl-1,1-dioxo-thietan-3-yl)-2-oxo-indoline-5-carboxamide,
1-(2-(3,3-difluoroazetidin-1-yl)-3-fluoropyridin-4-yl)-3,3-dimethyl-*N*-(3-methyl-1,1-dioxidothietan-3-yl)-2-oxoindoline-5-carboxamide,
1-(4-acetamido-3-hydroxyphenyl)-3,3-dimethyl-*N*-(3-methyl-1,1-dioxidothietan-3-yl)-2-oxoindoline-5-carboxamide,
(*R*)-*N*-(1-(2,2-difluoroethyl)-3-methylpiperidin-3-yl)-1-(3-(difluoromethoxy)phenyl)-3,3-dimethyl-2-oxoindoline-5-carboxamide,
1-(3-(difluoromethoxy)phenyl)-3,3-dimethyl-*N*-(3-methyl-1-(methylsulfonyl)piperidin-3-yl)-2-oxoindoline-5-carboxamide,
(*R*)-*N*-(1-acetyl-3-methylpiperidin-3-yl)-1-(3-(difluoromethoxy)phenyl)-3,3-dimethyl-2-oxoindoline-5-carboxamide,

1-(3-(difluoromethoxy)phenyl)-*N*-(4-methoxy-4-(trifluoromethyl)cyclohexyl)-3,3-dimethyl-2-oxoindoline-5-carboxamide,

7-cyano-1-(3-(difluoromethoxy)phenyl)-3,3-dimethyl-*N*-(3-methyl-1,1-dioxidothietan-3-yl)-2-oxoindoline-5-carboxamide,

1-(3-(difluoromethoxy)phenyl)-3,3-dimethyl-*N*-(4-methyl-1,1-dioxidotetrahydro-2*H*-thiopyran-4-yl)-2-oxo-2,3-dihydro-1*H*-pyrrolo[2,3-*c*]pyridine-5-carboxamide,

1-(3-(difluoromethoxy)phenyl)-6-fluoro-3,3-dimethyl-*N*-(4-methyl-1,1-dioxidotetrahydro-2*H*-thiopyran-4-yl)-2-oxoindoline-5-carboxamide,

7-(3-(difluoromethoxy)phenyl)-5,5-dimethyl-*N*-(4-methyl-1,1-dioxidotetrahydro-2*H*-thiopyran-4-yl)-6-oxo-6,7-dihydro-5*H*-pyrrolo[2,3-*c*]pyridazine-3-carboxamide,

1-(2-(2,2-difluoroethoxy)-5-fluoropyridin-4-yl)-3,3-dimethyl-*N*-(4-methyl-1,1-dioxidotetrahydro-2*H*-thiopyran-4-yl)-2-oxoindoline-5-carboxamide,

1-(4-(2,2-difluoroethoxy)pyridin-2-yl)-3,3-dimethyl-*N*-(4-methyl-1,1-dioxidotetrahydro-2H-thiopyran-4-yl)-2-oxoindoline-5-carboxamide,

3,3-dimethyl-*N*-(4-methyl-1,1-dioxidotetrahydro-2*H*-thiopyran-4-yl)-2-oxo-1-(4-(1,1,2,2-tetrafluoroethoxy)pyridin-2-yl)indoline-5-carboxamide,

1-(2-(2,2-difluoroethoxy)-5-fluoropyridin-4-yl)-6-fluoro-3,3-dimethyl-*N*-(4-methyl-1,1-dioxidotetrahydro-2*H*-thiopyran-4-yl)-2-oxoindoline-5-carboxamide,

1-(2-ethoxy-5-fluoropyridin-4-yl)-6-fluoro-3,3-dimethyl-*N*-(4-methyl-1,1-dioxidotetrahydro-2*H*-thiopyran-4-yl)-2-oxoindoline-5-carboxamide,

1-(2-ethoxy-5-fluoropyridin-4-yl)-3,3-dimethyl-*N*-(3-methyl-1,1-dioxidothietan-3-yl)-2-oxoindoline-5-carboxamide,

3,3-dimethyl-*N*-(4-methyl-1,1-dioxidotetrahydro-2*H*-thiopyran-4-yl)-2-oxo-1-(4-(2,2,2-trifluoroethoxy)pyridin-2-yl)indoline-5-carboxamide,

1-(4-(2,2-difluoropropoxy)pyridin-2-yl)-3,3-dimethyl-*N*-(4-methyl-1,1-dioxidotetrahydro-2*H*-thiopyran-4-yl)-2-oxoindoline-5-carboxamide,

3,3-dimethyl-*N*-(4-methyl-1,1-dioxidotetrahydro-2*H*-thiopyran-4-yl)-2-oxo-1-(4-(2,2,3,3-tetrafluoropropoxy)pyridin-2-yl)indoline-5-carboxamide,

1-(4-((2,2-difluorocyclopropyl)methoxy)pyridin-2-yl)-3,3-dimethyl-*N*-(4-methyl-1,1-dioxidotetrahydro-2*H*-thiopyran-4-yl)-2-oxoindoline-5-carboxamide,

1-(4-((3,3-difluorocyclobutyl)methoxy)pyridin-2-yl)-3,3-dimethyl-*N*-(4-methyl-1,1-dioxidotetrahydro-2*H*-thiopyran-4-yl)-2-oxoindoline-5-carboxamide,

1-(4-cyclopropoxypyridin-2-yl)-3,3-dimethyl-*N*-(4-methyl-1,1-dioxidotetrahydro-2*H*-thiopyran-










4-yl)-2-oxoindoline-5-carboxamide,
1-(4-(difluoromethoxy)pyridin-2-yl)-3,3-dimethyl-*N*-(4-methyl-1,1-dioxidotetrahydro-2*H*-thiopyran-4-yl)-2-oxoindoline-5-carboxamide,
1-(2-(difluoromethoxy)-5-fluoropyridin-4-yl)-6-fluoro-3,3-dimethyl-*N*-(4-methyl-1,1-dioxidotetrahydro-2*H*-thiopyran-4-yl)-2-oxoindoline-5-carboxamide,
3,3-dimethyl-*N*-(4-methyl-1,1-dioxidotetrahydro-2*H*-thiopyran-4-yl)-2-oxo-1-(6-(2,2,2-trifluoroethoxy)pyrimidin-4-yl)indoline-5-carboxamide,
1-(5-(difluoromethoxy)pyridin-3-yl)-3,3-dimethyl-*N*-(4-methyl-1,1-dioxidotetrahydro-2*H*-thiopyran-4-yl)-2-oxoindoline-5-carboxamide,
3,3-dimethyl-*N*-(4-methyl-1,1-dioxidotetrahydro-2*H*-thiopyran-4-yl)-2-oxo-1-(5-(trifluoromethoxy)pyridin-3-yl)indoline-5-carboxamide,
1-(2-(difluoromethoxy)-5-fluoropyridin-4-yl)-3,3-dimethyl-N-(4-methyl-1,1-dioxidotetrahydro-2H-thiopyran-4-yl)-2-oxoindoline-5-carboxamide,
1-(2-(difluoromethoxy)-5-fluoropyridin-4-yl)-6-fluoro-3,3-dimethyl-N-(3-methyl-1,1-dioxidothietan-3-yl)-2-oxoindoline-5-carboxamide,
1-(2-(2,2-difluoroethoxy)-5-fluoropyridin-4-yl)-3,3-dimethyl-*N*-(1-((methylsulfonyl)methyl)cyclobutyl)-2-oxoindoline-5-carboxamide,
1-(4-(2,2-difluoroethoxy)-3-fluoropyridin-2-yl)-3,3-dimethyl-*N*-(4-methyl-1,1-dioxidotetrahydro-2*H*-thiopyran-4-yl)-2-oxoindoline-5-carboxamide,
1-(2-(2,2-difluoropropoxy)-5-fluoropyridin-4-yl)-3,3-dimethyl-*N*-(4-methyl-1,1-dioxidotetrahydro-2*H*-thiopyran-4-yl)-2-oxoindoline-5-carboxamide,
1-(5-(2,2-difluoroethoxy)pyridazin-3-yl)-3,3-dimethyl-*N*-(4-methyl-1,1-dioxidotetrahydro-2*H*-thiopyran-4-yl)-2-oxoindoline-5-carboxamide,
1-(4-(2,2-difluoroethoxy)pyrimidin-2-yl)-3,3-dimethyl-*N*-(4-methyl-1,1-dioxidotetrahydro-2*H*-thiopyran-4-yl)-2-oxoindoline-5-carboxamide,
1-(6-(2,2-difluoroethoxy)pyrimidin-4-yl)-3,3-dimethyl-*N*-(4-methyl-1,1-dioxidotetrahydro-2*H*-thiopyran-4-yl)-2-oxoindoline-5-carboxamide,
1-(5-(azetidin-1-yl)-2-fluorophenyl)-6-fluoro-3,3-dimethyl-*N*-(4-methyl-1,1-dioxidotetrahydro-2*H*-thiopyran-4-yl)-2-oxoindoline-5-carboxamide,
1-(4-isopropoxypyridin-2-yl)-3,3-dimethyl-*N*-(4-methyl-1,1-dioxidotetrahydro-2*H*-thiopyran-4-yl)-2-oxoindoline-5-carboxamide,
1-(4-((1-fluorocyclopropyl)methoxy)pyridin-2-yl)-3,3-dimethyl-*N*-(4-methyl-1,1-dioxidotetrahydro-2*H*-thiopyran-4-yl)-2-oxoindoline-5-carboxamide,

1-(4-(cyclopropylmethoxy)pyridin-2-yl)-3,3-dimethyl-*N*-(4-methyl-1,1-dioxidotetrahydro-2*H*-thiopyran-4-yl)-2-oxoindoline-5-carboxamide,
1-(4-isobutoxypyridin-2-yl)-3,3-dimethyl-*N*-(4-methyl-1,1-dioxidotetrahydro-2*H*-thiopyran-4-yl)-2-oxoindoline-5-carboxamide,
1-(4-(1,1-difluoroethyl)pyridin-2-yl)-3,3-dimethyl-*N*-(4-methyl-1,1-dioxidotetrahydro-2*H*-thiopyran-4-yl)-2-oxoindoline-5-carboxamide,
1-(5-fluoro-4-(1,1,2,2-tetrafluoroethoxy)pyridin-2-yl)-3,3-dimethyl-*N*-(4-methyl-1,1-dioxidotetrahydro-2*H*-thiopyran-4-yl)-2-oxoindoline-5-carboxamide,
1-(5-(1,1-difluoro-2-hydroxyethoxy)pyridin-3-yl)-3,3-dimethyl-*N*-(4-methyl-1,1-dioxidotetrahydro-2*H*-thiopyran-4-yl)-2-oxoindoline-5-carboxamide,
1-(2-(3,3-difluoroazetidin-1-yl)-5-fluoropyridin-4-yl)-6-fluoro-3,3-dimethyl-*N*-(4-methyl-1,1-dioxidotetrahydro-2*H*-thiopyran-4-yl)-2-oxoindoline-5-carboxamide,
1-(4-(2,2-difluoropropoxy)pyridin-2-yl)-6-fluoro-3,3-dimethyl-*N*-(4-methyl-1,1-dioxidotetrahydro-2*H*-thiopyran-4-yl)-2-oxoindoline-5-carboxamide,
1-(4-(difluoromethoxy)pyridin-2-yl)-6-fluoro-3,3-dimethyl-*N*-(4-methyl-1,1-dioxidotetrahydro-2H-thiopyran-4-yl)-2-oxoindoline-5-carboxamide,
1-(4-(2,2-difluoroethoxy)pyridin-2-yl)-6-fluoro-3,3-dimethyl-*N*-(4-methyl-1,1-dioxidotetrahydro-2*H*-thiopyran-4-yl)-2-oxoindoline-5-carboxamide,
1-(4-(difluoromethoxy)-5-fluoropyridin-2-yl)-3,3-dimethyl-*N*-(4-methyl-1,1-dioxidotetrahydro-2*H*-thiopyran-4-yl)-2-oxoindoline-5-carboxamide,
1-(4-(2,2-difluoropropoxy)-5-fluoropyridin-2-yl)-3,3-dimethyl-*N*-(4-methyl-1,1-dioxidotetrahydro-2*H*-thiopyran-4-yl)-2-oxoindoline-5-carboxamide,
1-(4-(2,2-difluoroethoxy)-5-fluoropyridin-2-yl)-3,3-dimethyl-*N*-(4-methyl-1,1-dioxidotetrahydro-2*H*-thiopyran-4-yl)-2-oxoindoline-5-carboxamide,
N-(4-(difluoromethyl)-1,1-dioxidotetrahydro-2*H*-thiopyran-4-yl)-1-(2-ethoxy-5-fluoropyridin-4-yl)-6-fluoro-3,3-dimethyl-2-oxoindoline-5-carboxamide,
1-(5-fluoro-2-isopropoxypyridin-4-yl)-3,3-dimethyl-*N*-(4-methyl-1,1-dioxidotetrahydro-2*H*-thiopyran-4-yl)-2-oxoindoline-5-carboxamide,
1-(3-(difluoromethoxy)phenyl)-*N*-((3-hydroxytetrahydrofuran-3-yl)methyl)-3,3-dimethyl-2-oxoindoline-5-carboxamide,
1-(3-(difluoromethoxy)phenyl)-3,3-dimethyl-*N*-(5-methyl-1,3,4-thiadiazol-2-yl)-2-oxoindoline-5-carboxamide,
1-(3-(difluoromethoxy)phenyl)-*N*-((1-ethyl-1*H*-pyrazol-4-yl)methyl)-3,3-dimethyl-2-





oxoindoline-5-carboxamide,
1-(3-cyclopropylphenyl)-3,3-dimethyl-*N*-(4-methyl-1,1-dioxidotetrahydro-2*H*-thiopyran-4-yl)-2-oxoindoline-5-carboxamide,
1-(3-isopropoxyphenyl)-3,3-dimethyl-*N*-(4-methyl-1,1-dioxidotetrahydro-2*H*-thiopyran-4-yl)-2-oxoindoline-5-carboxamide,
1-(3-fluorophenyl)-3,3-dimethyl-*N*-(4-methyl-1,1-dioxidotetrahydro-2*H*-thiopyran-4-yl)-2-oxoindoline-5-carboxamide,
1-(3-cyanophenyl)-3,3-dimethyl-*N*-(4-methyl-1,1-dioxidotetrahydro-2*H*-thiopyran-4-yl)-2-oxoindoline-5-carboxamide,
(*R*)-1-(3-(difluoromethoxy)phenyl)-3-hydroxy-*N*-(3-methyl-1,1-dioxidothietan-3-yl)-2-oxo-3-(trifluoromethyl)indoline-5-carboxamide,
(*S*)-1-(3-(difluoromethoxy)phenyl)-3-hydroxy-*N*-(3-methyl-1,1-dioxidothietan-3-yl)-2-oxo-3-(trifluoromethyl)indoline-5-carboxamide,
(*R*)-1-(3-(difluoromethoxy)phenyl)-3-hydroxy-3-methyl-*N*-(3-methyl-1,1-dioxidothietan-3-yl)-2-oxoindoline-5-carboxamide,
(*S*)-1-(3-(difluoromethoxy)phenyl)-3-hydroxy-3-methyl-*N*-(3-methyl-1,1-dioxidothietan-3-yl)-2-oxoindoline-5-carboxamide,
1-(3-(difluoromethoxy)phenyl)-3-methyl-*N*-(3-methyl-1,1-dioxidothietan-3-yl)-2-oxoindoline-5-carboxamide,
3,3-dimethyl-*N*-(4-methyl-1,1-dioxidotetrahydro-2*H*-thiopyran-4-yl)-1-(3-(*N*-methylsulfamoyl)phenyl)-2-oxoindoline-5-carboxamide,
1-(3-carbamoylphenyl)-3,3-dimethyl-*N*-(4-methyl-1,1-dioxidotetrahydro-2*H*-thiopyran-4-yl)-2-oxoindoline-5-carboxamide,
3,3-dimethyl-*N*-(4-methyl-1,1-dioxidotetrahydro-2*H*-thiopyran-4-yl)-1-(3-(methylsulfonyl)phenyl)-2-oxoindoline-5-carboxamide, ~~or~~
1-(3-(dimethylamino)phenyl)-3,3-dimethyl-*N*-(4-methyl-1,1-dioxidotetrahydro-2*H*-thiopyran-4-yl)-2-oxoindoline-5-carboxamide,
1-(3-(difluoromethoxy)phenyl)-3-fluoro-3-methyl-*N*-(3-methyl-1,1-dioxidothietan-3-yl)-2-oxoindoline-5-carboxamide,
1-[3-(difluoromethoxy)phenyl]-N-(3-hydroxy-1,1-dimethyl-butyl)-3,3-dimethyl-2-oxo-indoline-5-carboxamide,
1-[3-(difluoromethoxy)phenyl]-3,3-dimethyl-*N*-(5-methyl-1,1-dioxo-thiolan-3-yl)-2-oxo-indoline-5-carboxamide,

1-[3-(difluoromethoxy)phenyl]-3,3-dimethyl-*N*-(4-methyl-1,1-dioxo-thiolan-3-yl)-2-oxo-indoline-5-carboxamide, or
1-[3-(difluoromethoxy)phenyl]-3,3-dimethyl-*N*-(2-methylsulfonylcyclopentyl)-2-oxo-indoline-5-carboxamide.


~~27.~~29. The compound of claim ~~25~~27, or a pharmaceutically acceptable salt thereof, which is:


,

,

,

,

,

,

,

, or

.


~~28.~~30. The compound of claim ~~25~~27, or a pharmaceutically acceptable salt thereof, which is:


,

,

, or

~~, or a pharmaceutically acceptable salt thereof~~.


~~29.~~31. The compound of claim ~~25~~27, or a pharmaceutically acceptable salt thereof,

which is  .


~~30.~~32. The compound of claim 27~~25~~, or a pharmaceutically acceptable salt thereof,

which is  .


~~31.~~33. The compound of claim 27~~25~~, or a pharmaceutically acceptable salt thereof,

which is  .


~~32.~~34. The compound of claim 27~~25~~, or a pharmaceutically acceptable salt thereof,

which is  .


~~33.~~35. The compound of claim ~~25~~27, or a pharmaceutically acceptable salt thereof,

which is  .


~~34.~~36. The compound of claim ~~25~~27, or a pharmaceutically acceptable salt thereof,

which is  .


~~35.~~37. The compound of claim ~~25~~27, or a pharmaceutically acceptable salt thereof,

which is  .


~~36.~~38. The compound of claim ~~25~~27, or a pharmaceutically acceptable salt thereof,

which is  .


~~37.~~39. The compound of claim ~~25~~27, or a pharmaceutically acceptable salt thereof,

which is  .


~~38.~~40. The compound of claim ~~25~~27, or a pharmaceutically acceptable salt thereof,

which is  .

~~39.~~41. The compound of claim ~~25~~27, or a pharmaceutically acceptable salt thereof,

which is  .

~~40.~~42. The compound of claim ~~25~~27, or a pharmaceutically acceptable salt thereof,

which is  .

~~41.~~43. A composition for use in treating a condition selected from hepatic steatosis, nonalcoholic steatohepatitis (NASH), fibrosis, type-2 diabetes mellitus, obesity, hyperlipidemia, hypercholesterolemia, atherosclerosis, cognitive decline, dementia, cardiorenal diseases and heart failure comprising a compound of any of claims 1 to ~~40~~42, or a pharmaceutically acceptable salt thereof, and a pharmaceutically carrier.

~~42.~~44. A composition comprising a pharmaceutically acceptable carrier and a compound according to any one of claims 1 to ~~40~~42, or a pharmaceutically acceptable salt thereof.

~~43. A method for treating a condition selected from hepatic steatosis, nonalcoholic steatohepatitis (NASH), fibrosis, type-2 diabetes mellitus, obesity, hyperlipidemia, hypercholesterolemia, atherosclerosis, cognitive decline, dementia, cardiorenal diseases and heart failure comprising administering to a patient in need thereof of a therapeutically effective amount of a compound of any of claims 1 to 40, or a pharmaceutically acceptable salt thereof.~~

~~44.~~45. Use of a compound of any of claims 1 to ~~40~~42, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating a condition selected from hepatic steatosis, nonalcoholic steatohepatitis (NASH), fibrosis, type-2 diabetes mellitus, obesity, hyperlipidemia, hypercholesterolemia,

atherosclerosis, cognitive decline, dementia, cardiorenal diseases and heart failure.